Science Explorer Back to mapMap
Discussion
Company · Lexington · United States

Cyteir Therapeutics (United States)

Research works
13
▼ 87% vs 2018-21
Citations
51
3.8 per fractional work
Top-10% rate
2.7%
all institutions 10.0%
Open access
14%
world 40%
International
6%
world 18%

Not ranked overall: Cyteir Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Cyteir Therapeutics (United States) work in?

In all years, 68% of research at Cyteir Therapeutics (United States) is in Life Sciences, 32% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (66%), Medicine (32%), Immunology and Microbiology (2%). It does 2.4× the world's share of Life Sciences.

Life Sciences68%Health Sciences32%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 4 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology965.8%
    2. Immunology and Microbiology02.5%
    1. Medicine431.6%
    1. Economics, Econometrics and Finance00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Who are the top researchers at Cyteir Therapeutics (United States)?

Ranked on the quality score, Melinda A. L. Day and Tyler M. Maclay lead among researchers whose main affiliation is Cyteir Therapeutics (United States).

  1. 1 Melinda A. L. Day United States · #1,976,126 worldwide 86 citations · 23 works
  2. 2 Tyler M. Maclay United States · #2,352,075 worldwide 35 citations · 16 works
All ranked researchers at Cyteir Therapeutics (United States)

What are the most cited papers from Cyteir Therapeutics (United States)?

The most cited paper from Cyteir Therapeutics (United States) is "Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry" (John P. Guilinger et al., 2021), with 46 citations. Next come "Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes" (38) and "Enhancing the efficacy of glycolytic blockade in cancer cellsviaRAD51 inhibition" (27).

Most cited papers
#PaperReleasedCitations
1 Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry John P. Guilinger et al. · Bioorganic & Medicinal Chemistry Open access 19 May 2021 46
2 Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes Jeremy J. Ratiu, Jeremy J. Racine, Muneer G. Hasham et al. · The Journal of Immunology Open access 2 May 2017 38
3 Enhancing the efficacy of glycolytic blockade in cancer cellsviaRAD51 inhibition John J. Wilson, Kin-Hoe Chow, Nathan J. Labrie et al. · Cancer Biology & Therapy Open access 5 Sep 2018 27
4 Identification of the mechanism of action of CYT-0851, an inhibitor of monocarboxylate transporter (MCT) mediated lactate transport B. Bradley, M.A. Belmonte, S. Kansara et al. · European Journal of Cancer Open access Oct 2022 3
All 4 most cited papers, with filters and sorting

Which research topics does Cyteir Therapeutics (United States) publish most on?

By volume in 2022-now: Cancer, Hypoxia, and Metabolism, RNA Research and Splicing, Metabolomics and Mass Spectrometry Studies and Advanced Breast Cancer Therapies.

  1. 1 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
  2. 2 RNA Research and Splicing Molecular Biology 0 works
  3. 3 Metabolomics and Mass Spectrometry Studies Molecular Biology 0 works
  4. 4 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
  5. 5 Protein Degradation and Inhibitors Molecular Biology 0 works
  6. 6 14-3-3 protein interactions Molecular Biology 0 works
  7. 7 Peptidase Inhibition and Analysis Oncology 0 works
  8. 8 Cancer Treatment and Pharmacology Oncology 0 works
  9. 9 Colorectal Cancer Treatments and Studies Oncology 0 works
  10. 10 PARP inhibition in cancer therapy Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available13.8%not open86.2%

World: 40% of research is openly available.

with international co-authors5.5%domestic only94.5%

World: 18% is written across borders.

How has Cyteir Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 87% lower than in 2018-2021.

2020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Lexington

All research institutions in Lexington

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Cyteir Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.